Swedes google CBD for anxiety, for pain, for sleep and for high blood pressure. We collected 2,301 search suggestions from Google's Swedish autocomplete and 3,372 actual queries from Search Console to see what the questions are about. The answer is unambiguous: effect. And effect is precisely what every lawfully operating seller in Sweden is forbidden to address. The gap between the question and the permitted answer is this industry's most underestimated problem.

What the questions are actually about

Google Autocomplete reports no volumes, only that a suggestion exists and has therefore been requested often enough for the system to offer it. The method is simple: we began with twenty common Swedish search terms, among them "cbd", "cbd olja", "cbd sverige", "hampaolja" and "cannabinoider". Each was then typed into the search box followed by one letter at a time, first a, then b, then c and on through the alphabet, and finally with question words meaning "what" and "how". Google fills in the rest itself. That produced 2,301 distinct search phrases.

Cluster them and a clear pattern emerges. The most common suggestions are of the type "cbd effekt på kroppen" (CBD's effect on the body), "cbd mot ångest" (CBD for anxiety), "cbd olja mot smärta" (CBD oil for pain), "cbd kräm mot smärta" (CBD cream for pain), "cbd mot högt blodtryck" (CBD for high blood pressure) and "cbd mot nervsmärta" (CBD for nerve pain). Then comes dosage: "hur mycket cbd per dag" (how much CBD per day). Then safety: "cbd olja biverkningar" (CBD oil side effects).

One thing has to be said plainly, or the point of this article is lost: that a question is asked often says nothing about whether the answer is yes. Search volume is not evidence. The list above describes what people wonder, not what has been shown. Conflating the two is exactly the error the legislation we are about to examine exists to prevent.

The prohibition is the default, not the exception

Most people assume the rules forbid false health claims. They do not. The prohibition covers claims that have not been expressly authorised, whether or not they happen to be true.

EU Regulation 1924/2006 defines a health claim very broadly, as any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health. The words "suggests or implies" are what make the provision so wide. Avoiding a direct assertion is not enough.

The default rule sits in Article 10(1): health claims shall be prohibited unless they are authorised in accordance with the Regulation and included in the lists of permitted claims provided for in Articles 13 and 14. The order is therefore the reverse of what many assume. A claim is forbidden until it appears on the list.

For cannabidiol, nothing appears on the list.

The scope follows from Article 1(2): the Regulation applies to claims made "in commercial communications", whether in labelling, presentation or advertising. That boundary is why a trade publication may describe the legal position while a seller may not do so on a product page.

"But our product is not a food"

Here the sector makes a mistake worth pausing on. Since 1924/2006 concerns food, it is tempting to conclude that a product not marketed as food falls outside it.

It does not. What counts as a food is not decided by the seller's framing but by Regulation 178/2002, which in Article 2 defines food as any substance or product, whether processed, partially processed or unprocessed, intended to be, or reasonably expected to be, ingested by humans. The second limb is the decisive one. A powder that consumers can reasonably be expected to swallow is a food, even if the packaging never mentions eating and never states a dose.

And a product that genuinely did fall outside would be in a worse position, not a better one. The medicines definition catches it instead: a product sold with claims that it prevents or treats disease is a medicinal product. It is the claim itself that makes the product a medicine, by presentation. A breach of 1924/2006 is a marketing infringement. Selling an unauthorised medicinal product is something else entirely.

For products applied to the skin, the Cosmetics Regulation 1223/2009 closes the same door. Article 20 provides that text, names, trade marks and pictures must not imply characteristics or functions the product does not have, and a therapeutic claim moves the product out of the cosmetics category and into medicines law altogether.

The three regimes are built to overlap. There is no gap to stand in.

And then the second door

Food law is only half the picture. The other half is medicines law, and for most people it is considerably more surprising.

On its page about cannabidiol, the Swedish Medical Products Agency states that it has on several occasions decided that CBD products intended to be taken orally or inhaled are medicinal products. A product is a medicinal product either if it has medical effects on the body, or if it is sold with claims that it prevents or treats disease. The agency adds that if it appears to the customer that the product is meant to treat disease, that too can make it a medicinal product.

Then comes the sentence few in the industry seem to have read. Because CBD is known to treat certain conditions, the agency writes, merely highlighting that the product contains it can be enough to make it a medicinal product under the second limb of the definition.

Read that again. Highlighting the content can suffice. Not claiming anything about it. Simply drawing attention to the presence of CBD can, on the agency's own wording, be enough for the product to be classified as a medicine and therefore require authorisation before sale. The agency also notes that it has in several cases prohibited companies from selling CBD oils that were not authorised.

The narcotics boundary sits alongside this and follows THC, not CBD. The agency puts it briefly: THC falls under narcotics legislation, CBD falls under medicines legislation. It refers to the Supreme Court ruling in case B 177-19, which held that the industrial hemp exemption does not extend to preparations, so CBD oils that also contain THC are narcotics.

In the same section the agency writes that the industrial hemp exemption is limited to varieties with a THC content below 0.2 per cent. That figure no longer holds. EU Regulation 2021/2115, governing agricultural support from 2023, sets the threshold at 0.3 per cent and justifies the requirement by reference to protecting public health and ensuring consistency with other legislation. The agency's page was published in February 2020 and last updated in June of that year, which is the likely explanation.

It is a small detail, but it points the same way as the rest of this article. If the authority meant to guide consumers is three years behind the threshold it describes, it is hard to expect the consumer to navigate this correctly unaided.

Two authorised medicines, and that is the whole list

Cannabidiol may lawfully be connected to disease in Sweden. It just is not something you buy off a shelf.

Epidyolex received EU marketing authorisation on 19 September 2019 and is, according to the European Medicines Agency, prescription-only, indicated for certain rare forms of epilepsy in patients from two years of age, and started under the supervision of a physician experienced in treating epilepsy. Sativex, containing both CBD and THC, is the other. The Swedish agency lists both.

The difference between these and a consumer product is not marginal. It concerns documented dose, controlled manufacture, an authorised indication and a regulator that has examined the evidence. That difference is why a company without the documentation may not borrow the indication.

What the authorities have actually said

Here lies one of the sector's most common confusions. Official statements about CBD do exist. They simply are not about what people search for.

The World Health Organization's Expert Committee on Drug Dependence concluded in its critical review of June 2018 that in humans, cannabidiol exhibits no effects indicative of any abuse or dependence potential, that the substance is generally well tolerated with a good safety profile, and that at the time of the report no public health problems had been associated with the use of pure CBD.

Those are statements about safety and abuse liability. They say nothing about efficacy against anxiety, pain or sleep, and cannot be used as though they did.

EFSA published a provisional safe intake level in February 2026 of 0.0275 milligrams per kilogram of body weight per day, roughly 2 milligrams per day for a 70 kg adult. That too is a safety assessment, not an authorisation. CBD remains under assessment as a novel food, with applications handled one at a time.

The sequence that locks the position in place

Anyone wanting to make a lawful health claim about CBD in the EU has to pass two gates in order, and the first is still shut.

The ingredient must first obtain authorised novel food status. Only then does it become meaningful to apply for a health claim under Article 13 or 14, a process requiring EFSA to assess the scientific substantiation. As long as gate one has not been cleared, there is no route through gate two.

The result is a situation that holds itself in place. The questions remain, in their thousands on our measurement, and the lawful market may not touch them.

What fills the vacuum

The vacuum is not empty. It shows up in our own material.

Among the collected suggestions are "cbd sverige flashback", "cbd olja mot ångest flashback" and "cbd olja effekt flashback", all pointing to Sweden's largest anonymous discussion forum. When the regulated part of the market may not answer, people turn to forums, to unregulated resellers and to foreign sites indifferent to Swedish supervision. The answers are there, without sourcing requirements, without liability, and without anyone checking the dose.

That is the uncomfortable conclusion. The regulation does exactly what it was written to do: it stops sellers promising things they cannot substantiate. But it only stops the ones who comply. The effect is that the most responsible operator is the one least visible in precisely those searches where unsafe advice does the most damage.

We have no ready solution to offer. But the debate about these rules is almost always conducted as a question of what companies may say. It ought also to be conducted as a question of who answers when they stay silent.

About the data

The search suggestions were retrieved on 29 August 2026 from Google's open search-suggestion interface, using Swedish language and country settings. Twenty search terms were combined with each letter of the alphabet and with question words, producing 2,301 distinct search phrases. The Search Console data covers 3,372 unique queries for the period 28 February to 27 August 2026 for a single Swedish hemp site, and therefore describes that site's visibility rather than the market as a whole. No searches are linked to individuals. Autocomplete reports no volumes, so the material shows the direction of the questions rather than their size.

This article describes the applicable regulatory framework for journalistic purposes. It does not constitute legal or medical advice, and no health claims about any product follow from it. See Ownership and transparency for Svenskhampa's relationship with Helsama.